Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ Dec 8, 2023 12:55PM
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease Dec 8, 2023 12:52PM
Vertex Pharma (VRTX) and CRISPR Therapeutics (CRSP) Announce Authorization of the CASGEVY in the UK Nov 16, 2023 04:53AM
 Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Nov 16, 2023 01:45AM
Vertex Pharma (VRTX) Announces FDA Acceptance of BLA for exagamglogene autotemcel for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Jun 9, 2023 05:35AM
View Older Stories

Jun 9, 2023 05:29AM Vertex Pharma (VRTX) Reports Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease
Jun 9, 2023 03:01AM Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
Jun 8, 2023 07:23PM FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Apr 3, 2023 08:01AM Vertex Pharma (VRTX), CRISPR Therapeutics (CRSP) Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion
Apr 3, 2023 08:00AM Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Th
Mar 27, 2023 08:02AM Vertex Pharma (VRTX), CRISPR Therapeutics (CRSP) Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
Mar 27, 2023 08:00AM Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
Dec 10, 2022 08:00AM Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
Sep 27, 2022 07:29AM Vertex Pharma (VRTX) and CRISPR (CRSP) Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia
Sep 27, 2022 07:29AM Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
Jun 11, 2022 03:00AM Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
Jun 2, 2022 10:06AM Vertex Pharma (VRTX), CRISPR Therapeutics (CRSP) Announce Acceptance of Late-Breaking Abstract for CTX001 at EHA
Jun 2, 2022 10:05AM Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
Feb 2, 2022 08:30AM CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)
Nov 16, 2021 08:30AM CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes
Nov 10, 2021 05:05PM IMV Inc. Announces Third Quarter 2021 Financial and Operational Update
Jun 11, 2021 03:05AM Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematolo
May 12, 2021 11:01AM Vertex (VRTX) and CRISPR Therapeutics (CRSP) to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 For Severe Hemoglobinopathies at EHA
May 12, 2021 11:00AM Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Vi
Apr 26, 2021 08:33AM Vertex (VRTX) and CRISPR Therapeutics (CRSP) Announce PRIME Designation Granted by EMA to CTX001 for Transfusion-Dependent Beta Thalassemia
Apr 26, 2021 08:30AM Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Apr 20, 2021 07:39AM Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell Disease and Beta Thalassemia
Apr 20, 2021 07:15AM Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia
Dec 5, 2020 12:30PM CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publicati
Dec 1, 2020 09:00AM CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Edi
Nov 4, 2020 09:15AM CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition
Sep 22, 2020 09:01AM CRISPR Therapeutics (CRSP), Vertex Pharmaceuticals (VRTX) Announce PRIME Designation Granted by EMA to CTX001 for Treatment of Sickle Cell Disease
Sep 22, 2020 09:00AM CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease
Jun 12, 2020 06:10AM CRISPR Therapeutics (CRSP), Vertex Pharma (VRTX) Highlight New Clinical Data for Investigational Gene-Editing Therapy CTX001 in Severe Hemoglobinopathies
Jun 12, 2020 02:30AM CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congr
May 14, 2020 09:02AM New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress
May 11, 2020 09:05AM CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX) Announce FDA RMAT Designation Granted to CTX001 for Treatment of Severe Hemoglobinopathies
May 11, 2020 09:00AM CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies
Nov 19, 2019 07:02AM CRISPR Therapeutics (CRSP), Vertex (VRTX) Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobino
Nov 19, 2019 07:00AM CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
Sep 10, 2018 04:34PM CRISPR (CRSP), Intellia (NTLA) and Caribou Provide Update on U.S Federal Circuit Decision Upholding Ruling by USPTO in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology
Sep 10, 2018 04:30PM CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Re
Jun 19, 2018 09:07AM CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA) and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing
Jun 19, 2018 09:05AM CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing
Apr 17, 2018 09:22AM Pre-Open Movers 04/17: (RNDA) (ROKU) (NFLX) Higher; (BLCM) (LADR) (SEAC) Lower (more...)
Jan 23, 2018 09:23AM Pre-Open Movers 01/23: (RGSE) (CNET) (NFLX) Higher; (GPRO) (ADMS) (TWTR) Lower (more...)
Jul 25, 2017 05:02PM CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing
Jul 25, 2017 05:00PM CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing
Apr 26, 2017 07:37AM Intellia (NTLA), CRISPR Therapeutics (CRSP) Receive U.S. Patent for CRISPR/Cas9 Ribonucleoprotein Complexes
Apr 26, 2017 07:30AM Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes
Apr 13, 2017 07:36AM CRISPR (CRSP), Intellia (NTLA), Caribou, and ERS Genomics Appeal CRISPR/Cas9 U.S. Patent Board Decision
Apr 13, 2017 07:30AM CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision
Feb 15, 2017 03:19PM CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.
Feb 15, 2017 02:51PM CRISPR (CRSP), Intellia (NTLA), Caribou, ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings
Feb 15, 2017 02:49PM CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.
View Older Stories